Consensus I-Mab

Equities

IMAB

US44975P1030

Delayed Nasdaq Other stock markets 03:55:11 2024-05-17 pm EDT			5-day change	1st Jan Change
1.75 ^USD	-1.13%		-1.69%	-7.89%

Apr. 18	Verastem Names John Hayslip as Chief Medical Officer	MT
Apr. 15	I-Mab Announces Chief Medical Officer Changes	CI

Evolution of the average Target Price on I-Mab

Price target over the last 5 years

History of analyst recommendation changes

54ecbe03db04f2e5e.sO2FVNzVK4433IgdgJH2jS5MAGk1zLFDim7VpZsowTs.5ae8Yem0ZddB8etvufW99Hg6Vw5dgckX4S200vFrpF__oc4yiLJexAWovA~dd5f423bb72abd2bdf6ec7bb4455ea07

Analyst Recommendations on I-Mab

Piper Sandler Adjusts Price Target on I-Mab to $10 From $15, Maintains Overweight Rating	Mar. 18	MT
Needham Cuts Price Target on I-Mab to $6 From $8, Maintains Buy Rating	Mar. 15	MT
Needham Trims I-Mab Price Target to $23 From $24, Maintains Buy Rating	23-09-25	MT
HC Wainwright Adjusts Price Target on I-Mab to $18 From $25, Maintains Buy Rating	23-08-18	MT
Needham Lowers Price Target on I-Mab to $24 From $33, Maintains Buy Rating	23-04-03	MT
Piper Sandler Adjusts Price Target on I-Mab to $25 From $30, Maintains Overweight Rating	23-04-03	MT
HC Wainwright Adjusts Price Target on I-Mab to $25 From $45, Maintains Buy Rating	23-04-03	MT
MSCI ESG Updated I-Mab to 'A' Rating	23-03-08	AQ
MSCI ESG Updated I-Mab to "A" Rating	23-03-07	PR
I-Mab Says Combination Treatment for Myelodysplastic Syndrome Showed Overall Response Rate of 86.7% in Phase 2 Trial	22-09-12	MT
HC Wainwright Adjusts I-Mab's Price Target to $45 From $70, Maintains Buy Rating	22-08-31	MT
Needham Adjusts I-Mab's Price Target to $33 From $41, Reiterates Buy Rating	22-08-31	MT
Piper Sandler Adjusts I-Mab's Price Target to $30 From $35, Reiterates Overweight Rating	22-08-31	MT
Needham Lowers I-Mab's Price Target to $41 From $72, Maintains Buy Rating	22-08-17	MT
HC Wainwright Adjusts I-Mab's Price Target to $70 From $80, Keeps Buy Rating	22-05-31	MT
Piper Sandler Adjusts I-Mab's Price Target to $35 From $80, Reiterates Overweight Rating	22-05-31	MT
Needham Adjusts I-Mab's Price Target to $72 From $85, Reiterates Buy Rating	22-05-31	MT
HC Wainwright Adjusts I-Mab's Price Target to $80 from $95, Keeps Buy Rating	22-03-30	MT
Piper Sandler Adjusts I-Mab's Price Target to $80 From $90, Reiterates Overweight Rating	22-03-30	MT
SWS Research Starts I-Mab at Buy with $96 Price Target	21-12-09	MT
Needham Adjusts Price Target on I-Mab to $85 from $83, Keeps Buy Rating	21-11-01	MT
I MAB : HC Wainwright Adjusts I-Mab's Price Target to $95 from $75, Keeps Buy Rating	21-09-01	MT
I MAB : Cantor Fitzgerald Adjusts I-Mab PT to $95 From $90, Maintains Overweight Rating	21-07-13	MT
I MAB : Cantor Fitzgerald Adjusts I-Mab's Price Target to $90 From $76, Maintains Overweight Rating	21-06-10	MT
I MAB : Piper Sandler Adjusts I-Mab PT to $90 From $75, Maintains Overweight Rating	21-06-07	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.77 USD

Average target price

7.25 USD

Spread / Average Target

+309.60%

High Price Target

10 USD

Spread / Highest target

+464.97%

Low Price Target

5 USD

Spread / Lowest Target

+182.49%

Consensus detail

Consensus revision (last 18 months)

Analysts covering I-Mab

Piper Sandler
Needham & Co.
HC Wainwright
SWS Research
Cantor Fitzgerald
Daiwa Securities

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar